Bulevirtide FDA approval date

The FDA approved Bulevirtide (BJT-778) on 22 May 2026.

FDA approval date
22 May 2026

Drug identity checked against registry records

Also recorded as BJT-778; Hepcludex

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-05-22DayBulevirtideFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761468", "applicant_as_listed_by_fda": "GILEAD SCIENCES INC", "brand_names": ["HEPCLUDEX"], "active_ingredients": ["BULEVIRTIDE-GMOD"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260522", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026